

LAM Wai Kei Christopher



Position: Chair Professor, Vice Dean

*Director of Pathology and Clinical Laboratory
Researcher*

Faculty: Faculty of Medicine

*University Hospital
State Key Laboratory of Quality Research in
Chinese Medicines*

Email: wklam@must.edu.mo

Telephone: (853) 8897-2636

Fax No.: (853) 2882-5886

Office: P25-206

*Mailing
Address:* Macau University of Science and
Technology, Avenida Wai Long, Taipa,
Macao

Teaching Modules: *Laboratory Medicine, Pathophysiology*

Research Areas: *Laboratory Medicine, Chinese Medicine, Public Health*

After completing his education and training in clinical sciences in 1974, Professor Lam has taught laboratory medicine in universities and directed hospital pathology service for >30 years. He has published >650 SCI papers accruing a total citation number of >20,200 and an h-index of 69. His international academic and professional services include President of the Asian and Pacific Federation of Clinical Biochemistry (APFCB, 16 countries) and Vice President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC, 85 countries).

Academic Qualifications:

May 1969 BSc Honors in Chemistry (University of Hong Kong, Hong Kong)

August 1970 *MSc in Molecular Sciences (University of Warwick, UK)*
February 1974 *PhD in Immunology (University of Southampton, UK)*

Working Experience :

Since 2019.3 *Chair Professor and Vice Dean, Faculty of Medicine, Macau University of Science and Technology (MUST)*
Since 2011.3 *Director of Pathology and Clinical Laboratory, University Hospital, MUST*
2009.9 - 2011.6 *Director of Macau Institute for Applied Research in Medicine and Health, MUST*
2009.9 - 2019.2 *Professor / Chair Professor and Vice Dean, Faculty of Health Sciences, MUST*
1999 -2009 *Chinese University of Hong Kong and Prince of Wales Hospital*
 (1) Professor, Chairman and Chief of Service, Department of Chemical Pathology
 (2) Director of Clinical Immunology Unit
 (3) Assistant Dean of Medicine (Research)

Professional Memberships:

- 1) *Fellow of the Royal Society of Chemistry (UK, 1985)*
- 2) *Fellow of the Academy of Clinical Biochemistry (US, 1989)*
- 3) *Honorary Fellow, Hong Kong College of Pathologists (HK, 2004)*
- 4) *Honorary Fellow, Royal College of Pathologists (UK, 2006)*
- 5) *Listed Practitioner of Chinese Medicine (HK Government, 2001)*

Visiting Professorships:

- 1) *Beijing People's Liberation Army General Hospital (301 Hospital) and Postgraduate Medical School (since 2001)*
- 2) *Chongqing Medical University (since 2001)*
- 3) *Faculty of Medicine, The Chinese University of Hong Kong (since 2010)*

Awards:

- 1) *APFCB Silver Jubilee Distinguished Medal (2007)*
- 2) *IFCC Distinguished Award for Laboratory Medicine and Patient Care (2008, inaugural award from IFCC)*
- 3) *Merit Certificate (2010): Corresponding Author of 2006-2010 top-5 cited paper from*

Papers published in 2021 in SCI journals:

1. Gao X, Chan PKS, Lui GCY, Hui DSC, Chu IMT, Sun XY, Tsang MSM, Chan BCL, **Lam CWK**, Wong CK. Interleukin 38 ameliorates Poly (I:C) induced lung inflammation: Therapeutic implications in respiratory viral infections. *Cell Death & Disease* 2021 Jan 7; 12 (1):53. Doi:10.1038/s41419-020-03282-2. IF = 6.484.
2. Hou TH, Tsang MSM, Chu IMT, Kan LLY, Hon KL, Leung TF, **Lam CWK**, Wong CK. Skewed inflammation is associated with aberrant interleukin-37 signaling pathway in atopic dermatitis. *Allergy* 2021 Feb 7; 76:2102-14. IF=13.146.
3. Tomlinson B, Lin CH, Chan P, **Lam CWK (Co-Corresponding Author)**. Personalized medicine in lipid-modifying therapy. *Personalized Medicine* 2021 Feb 10; 18(2): 185-203. IF = 4.433.
4. Chen RH, Yang LJ, Hamdoun S, Chung S, Zhang KZ, **Lam CWK**, Guo SL, Xia CL, Law YK, Wong KW. 1,2,3,4,6-Pentagalloyl glucose, a RBD-ACE2 binding inhibitor to prevent SARS-CoV-2 infection. *Frontiers in Pharmacology* 2021 Mar 4; 12:634176. IF = 4.400.
5. Tomlinson B, Patil NG, Fok M, **Lam CWK (Co-Corresponding Author)**. Role of PCSK9 inhibitors in patients with familial hypercholesterolemia. *Endocrinol Metab Seoul* 2021 Apr; 36(2): 279-295. IF = 2.910.
6. Li Y, Zhang HX, Luo WD, **Lam CWK**, Wang CY, Bai LP, Wong VKW, Zhang W, Jiang ZH. Profiling ribonucleotide and deoxyribonucleotide pools perturbed by Remdesivir in human bronchial epithelial cells. *Front Pharmacol* 2021 May 4; 12:647280. IF = 5.810.
7. Hou TH, Tsang MSM, Kan LLY, Li PT, Chu AMT, **Lam CWK**, Wong CK. IL-37 targets TSLP-primed basophils to alleviate atopic dermatitis. *Int J Mol Sci* 2021 (July); 22:7393. IF = 5.920.
8. Wu XX, Siu WS, Wat CL, Chan CL, Koon CM, Li X, Cheng W, Tsang MSM, **Lam CWK**, Wong CK. Effects of topical application of a tri-herb formula on inflammatory dry-skin condition in mice with oxazolone-induced atopic dermatitis. *Phytomedicine* 91 (2021 July 28) 153691. IF = 5.340.

9. Chan SW, Tomlinson B, Chan P, **Lam CWK**. The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk. Pharm Biol 2021 (August); 59: 1161-71. IF = 2.971.
10. Tomlinson B, Chan P, **Lam CWK**. Is there still a role for sulfonylureas in type 2 diabetes? Current Pharmacogenomics and Personalized Medicine (Accepted 21 September 2021). IF = 1.14.
11. Tomlinson B, Chan P, **Lam CWK (Co-Corresponding Author)**. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opin Pharmacother 2021 Oct 11:1-14. IF = 3.889.
12. Tomlinson B, Chow E, Cahn P, **Lam CWK (Co-Corresponding Author)**. An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Exp Opin Drug Metab Toxicol. Accepted 2021 Oct 20. IF = 4.481.
13. Guo X, Leung TF, Wong GWK, Ko WH, Cai MY, Je EJY, Chu IMT, Tsang MSM, Chan BCL, Ling JW, Fan X, Lu LW, **Lam CWK**, Wong CK. Meteorin-beta/Meteorin-like/IL-41 attenuates airway inflammation in house dust mite-induced allergic asthma. Cellular & Molecular Immunology accepted 28 October 2021. IF = 11.53.
14. Tomlinson B, Chan P, Lam CWK (**Co-Corresponding Author**). The role of sulfonylureas in the treatment of type-2 diabetes. Expert Opin Pharmacother 2021 Nov 10:1-17. IF = 3.889.
15. Tomlinson B, Patil NG, Fok M, **Lam CWK (Co-Corresponding Author)**. Managing dyslipidemia in patients with type 2 diabetes. Expert Opin Pharmacother 2021 Nov 22 (16): 2221-2234. IF = 3.889.
16. Ling JW, Chan BCL, Tsang MSM, Gao X, Leung PC, **Lam CWK**, Hu JM, Wong CK. Current advances in the mechanisms and treatment of dry eye disease: towards anti-inflammatory and immune-modulating therapy and traditional Chinese medicine. Frontiers in Medicine. Accepted December 27, 2021. IF=5.093.